References
- Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc 2015;90:500-4
- Mailankody S, Prasad V. Five years of cancer drug approvals innovation, efficacy, and costs. JAMA Oncol 2015;1:539-40
- Gordon N, Stemmer SM, Greenberg D, et al. Trajectories of injectable cancer drug costs after launch in the United States. J Clin Oncol 2018;36:319-25
- Barnes TA, Amir E, Templeton AJ, et al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev 2017;56:1-7
- Venkatesan P. Pricing increases for cancer drugs sparks investigation. Lancet 2017;18:e372
- Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 2017;359:j4530
- Grössmann N, Wild C. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open 2017;1:e000125
- Merseburger AS, Haas GP, von Klot C-A. An update on enzalutamide in the treatment of prostate cancer, Ther Adv Urol 2015;7:9-21
- Wu M, Sirota M, Butte AJ, et al. Characteristics of drug combination therapy in oncology by analyzing clinical trial data on clinicaltrials.gov. Biocomputing 2015. November 2014, 68-79. Available at: https://www.worldscientific.com/doi/pdf/10.1142/9789814644730_0008 [Last accessed 22 July 2018]
- Haycox A. Why cancer? Pharmacoeconomics 2016;347:625-7
- Global oncology trend report. A review of 2015 and outlook to 2020. IMS Institute for Healthcare Informatics, USA. Available at: www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/globaloncology-trend-report-a-review-of-2015-and-outlook-to-2020# [Last accessed 11 August 2017]
- New 50 million pound cancer fund already intellectually bankrupt. Lancet 2010;376:389
- Goldman DP, Joyce GF, Lawless G, et al. Benefit design and specialty drug use. Health Aff (Millwood) 2006;25:1319-31
- Culler SD, Weintraub WS. Is initiation of atorvastatin for employees a good buy for employers? Mayo Clin Proc 2009;84:1059-61
- Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015;8:77-94
- Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st century cancer drug pricing. J Clin Oncol 2009;27:2111-13
- Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2015;2:e408-16
- Petrou P. Value-based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and axitinib. Pharmacol Res 2017;124:160-3
- Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet 2017;389:403-7
- Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001. Available at: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf [Last accessed 22 July 2018]
- Waxman H, Durbin RJ, Kennedy EM. New GAO analysis of drug development refutes industry myths. Washington DC: U.S. Congress; 2006
- DiMasi JA, Hansen RW, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85
- Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42
- Keyhani S, Diener-West M, Powe N. Are development times for pharmaceuticals increasing or decreasing? Health Affairs 2006;25:461-8
- Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-73
- Wild C, Grossmann N, Bonanno, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol 2016;27(11):2134-6
- Ferguson JS, Summerhayes M, Masters S, et al. New treatments for advanced cancer: an approach to prioritization. Br J Cancer 2000;83:1268-73